Project 1 will seek to identify genetic modifiers of Facioscapulohumeral muscular dystrophy by focusing on nonmanifesting earners of the 4qA allele. Several carriers of the 4q161PAS allele have been identified in Italy who have no manifestations nor family history of the disease. In addition, our Wellstone Center has identified families containing affected and nonmanifesting relatives who share the same allele and similarly express DUX4-FL in skeletal muscle. These individuals suggest that the current genetic signature of FSHD (D4Z4 contraction in the presence of the 4qA allele and a polyadenylation sequence in a distal pLAM sequence) is not an exclusive determinant of FSHD and that there is either a """"""""second-hit"""""""" resulting in disease or a protective gene resulting in muscle health. Project 1 has two broad aims.
The first aim i s to identify and characterize nonmanifesting carriers of the FSHD allele. 10 nonmanifesting carriers without family history have been identified and examined in Italy and 4 nonmanifesting carriers from FSHD families have been identified and examined in the U.S. to date. Additional subjects will be recruited from the FSH Society and a large epidemiological study by the Italian National Registry for FSHD. Subjects will have detailed genotypic and phenotypic characterization including determination of DUX4-fl expression, muscle strength, muscle histopathology and muscle imaging.
The second aim will identify genetic modifiers of FSHD through the use of whole-exome sequencing of nonmanifesting and affected individuals. In addition to an unbiased analysis of all -20,000 human genes, we will also test targeted hypotheses regarding whether variants in any of the ~300 known muscle-disease related genes are associated with FSHD manifestion, singly or collectively. Project 1 will interact closely with Project 2 where RNAseq will generate RNA sequence information that will confirm and add to the exome sequence data to identify genetic changes related to modifiers. Project 1 will also identify subjects that will be the source of donation of muscle and myoblasts for xenografts in Project 3. Finally, Project 1 will be assisted by the Cell Core which will provide histopathological analysis and CD56 myoblasts FACS sorted from muscle biopsy specimens.

Public Health Relevance

The occurrence of nonmanifesting carriers of a permissive FSHD allele suggests that there are important modifiers to the development of weakness. This project will identify, characterize and sequence the exome of these individuals with the goal of identifying genetic modifiers. Modifiers of disease will be excellent future therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HD060848-08
Application #
8734465
Study Section
Special Emphasis Panel (ZNS1-SRB-S)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
8
Fiscal Year
2014
Total Cost
$245,290
Indirect Cost
$18,346
Name
University of Massachusetts Medical School Worcester
Department
Type
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Leung, Doris G; Wang, Xin; Barker, Peter B et al. (2018) Multivoxel proton magnetic resonance spectroscopy in facioscapulohumeral muscular dystrophy. Muscle Nerve 57:958-963
Wallace, Lindsay M; Saad, Nizar Y; Pyne, Nettie K et al. (2018) Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev 8:121-130
Giesige, Carlee R; Wallace, Lindsay M; Heller, Kristin N et al. (2018) AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight 3:
Chagarlamudi, Hema; Corbett, Alastair; Stoll, Marion et al. (2017) Bone health in facioscapulohumeral muscular dystrophy: A cross-sectional study. Muscle Nerve 56:1108-1113
Eichinger, Katy; Heatwole, Chad; Heininger, Susanne et al. (2017) Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy. Muscle Nerve 55:333-337
Ansseau, Eugénie; Vanderplanck, Céline; Wauters, Armelle et al. (2017) Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD). Genes (Basel) 8:
Shaw, Natalie D; Brand, Harrison; Kupchinsky, Zachary A et al. (2017) SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome. Nat Genet 49:238-248
Chen, Jennifer Cj; King, Oliver D; Zhang, Yuanfan et al. (2016) Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics. Mol Ther 24:1405-11
Ansseau, Eugénie; Eidahl, Jocelyn O; Lancelot, Céline et al. (2016) Homologous Transcription Factors DUX4 and DUX4c Associate with Cytoplasmic Proteins during Muscle Differentiation. PLoS One 11:e0146893
Sakellariou, Paraskevi; O'Neill, Andrea; Mueller, Amber L et al. (2016) Neuromuscular electrical stimulation promotes development in mice of mature human muscle from immortalized human myoblasts. Skelet Muscle 6:4

Showing the most recent 10 out of 34 publications